T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural MesotheliomaPhotodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural MesotheliomaImmunotherapy in Malignant Pleural Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural MesotheliomaTumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
/in Dendritic Cells, International PublicationsMulti-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
/in Dendritic Cells, International PublicationsImmunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma, Newcastle Disease VirusSubstantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report
/in Dendritic Cells, International Publications, Prostate CancerTriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant MelanomaInterferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines
/in Dendritic Cells, Malignant Melanoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer